Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures.
Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Devi Nair, MD, director of cardiac electrophysiology with St. Bernard's Heart and Vascular Center, discussed her experience using a new-look Medtronic pulsed field ablation (PFA) system to treat persistent AFib.
Heart Rhythm Society President Jodie Hurwitz, MD, told Cardiovascular Business that pulsed field ablation was one of the hottest topics at Heart Rhythm 2024. It may be early, she said, but the technology is already making an impact.
Cardiologist Jerry Blackwell, MD, president and CEO of MedAxiom, believes cardiologist can't just focus on clinical decisions, as they also must be aware the financial ramifications.
One of the biggest decisions in a cardiologist's life is knowing when, exactly, to start a family. Nandita S. Scott, MD, co-director of the Corrigan Women's Heart Health Program at Mass General Hospital, shared her perspective on this important topic.
"I think we really need our cardiologist community to understand the changes that are happening with value-based payment," one expert tells Cardiovascular Business.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
